Avastin granted another license by the FDA
Genentech can do no wrong, these days. I've written extensively about Avastin in the past, and now they've been granted another license by the FDA today (and I'm starting to feel like a broken record):
The study showed that patients who received Avastin plus the 5-FU-based chemotherapy regimen known as FOLFOX4 (oxaliplatin/5-FU/leucovorin) had a 25 percent reduction in the risk of death (based on a hazard ratio of 0.75), the primary endpoint, which is equivalent to a 33 percent improvement in overall survival, compared to patients who received FOLFOX4 alone. Median survival for patients receiving Avastin plus FOLFOX4 was 13.0 months, compared to 10.8 months for those receiving FOLFOX4 alone.
Now we'll have to wait and see if the FDA approves Avastin for use in conjunction with taxane chemotherapy for treating colorectal cancer, as well.
[tags]Medicine, pharmacy, cancer, oncology, genentech, avastin, bevacizumab, colorectal cancer, chemotherapy[/tags]
No Comments »
No comments yet.
RSS feed for comments on this post.
| TrackBack URI
You can also bookmark
this on del.icio.us or check the cosmos